Manajemen Pemberian Dual Antiplatelet Therapy (DAPT) Pada Pasien Sindrom Koroner Akut Dengan Trombositopenia
ZH Yusa, M Muyasir - Journal of Medical Science, 2023 - rsudza.acehprov.go.id
Abstract Berdasarkan data Riset Kesehatan Dasar (Riskesdas) 2018, prevalensi penyakit
jantung koroner sebagai etiologi utama sindrom koroner akut (SKA) di Indonesia sebesar 1 …
jantung koroner sebagai etiologi utama sindrom koroner akut (SKA) di Indonesia sebesar 1 …
[HTML][HTML] Dual versus Single Antiplatelet Therapy in Medically Treated Acute Myocardial Infarction Patients with Baseline Thrombocytopenia–Insights from a Multi …
YY Lu, CL Wang, SH Chang, FC Hsiao… - Acta Cardiologica …, 2022 - ncbi.nlm.nih.gov
Background The safety and efficacy of dual antiplatelet therapy (DAPT) in medically treated
acute myocardial infarction (AMI) patients with baseline thrombocytopenia (platelet count< …
acute myocardial infarction (AMI) patients with baseline thrombocytopenia (platelet count< …
The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum
CP McCarthy, G Steg, DL Bhatt - European heart journal, 2017 - academic.oup.com
Dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 receptor antagonist is a
fundamental component of acute coronary syndrome (ACS) management, with longstanding …
fundamental component of acute coronary syndrome (ACS) management, with longstanding …
Comparison Between Mono VS Dual VS Triple Antiplatelet Therapy In Patients With Ischemic Heart Disease Undergoing PCI, A Network Meta-Analysis
AS Al-Shammari, A Ibrahim, L Shalabi, M Khan… - Current Problems in …, 2024 - Elsevier
Aims We aim to research the efficacy and safety of single (SAPT), dual (DAPT), and triple
(TAPT) antiplatelets approaches across IHD patients undergoing PCI. Methods and results A …
(TAPT) antiplatelets approaches across IHD patients undergoing PCI. Methods and results A …
[HTML][HTML] Antiaggregation Strategy post Coronary Angioplasty with Stent in a Patient with Severe Thrombocytopenia Estrategia de antiagregación post angioplastia …
M Rosati, A Salva, V López, M Aladio, S Swieszkowski - rac.sac.org.ar
Dual antiplatelet therapy is a key element in the pharmacological treatment of coronary heart
disease. It consists in the combination of aspirin (ASA) and a P2Y12 platelet inhibitor. This …
disease. It consists in the combination of aspirin (ASA) and a P2Y12 platelet inhibitor. This …
Optimal antiplatelet therapy for acute coronary syndrome patients with high risk for both ischemia and bleeding
Y Li, M Lei, J Wang, X Sun, C Li, Z Zhao, Z Xue - 2024 - researchsquare.com
Objective: To investigate the impact of different regimens of dual antiplatelet therapy (DAPT)
on the prognosis of acute coronary syndrome (ACS) patients with high risk of both ischemia …
on the prognosis of acute coronary syndrome (ACS) patients with high risk of both ischemia …
Dual Antiplatelet Therapy: Guidance for Nurse Practitioners
S O'Keefe, SK Idzik - The Journal for Nurse Practitioners, 2022 - Elsevier
Long-term dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor (clopidogrel,
prasugrel, or ticagrelor) is recommended after acute coronary syndrome (ACS) to reduce the …
prasugrel, or ticagrelor) is recommended after acute coronary syndrome (ACS) to reduce the …
[HTML][HTML] Terapi jangka panjang antiplatelet ganda (≥ 12 bulan) pada acute coronary syndrome sebagai pencegah sekunder terhadap major adverse cardiac event: a …
NPGR Sanjiwani, IGNP Gunadhi… - Intisari Sains …, 2021 - isainsmedis.ejournals.ca
Background: Long-term use of dual antiplatelet therapy increases the risk of bleeding but
reduces the risk of major adverse cardiac events. This systematic review will discuss the …
reduces the risk of major adverse cardiac events. This systematic review will discuss the …
Latest Developments in Cardiology
KP Jadhav, PV Jariwala - Indian Journal of Clinical …, 2021 - journals.sagepub.com
Background: Balancing the effects of dual antiplatelet therapy (DAPT) in the era of potent
P2Y12 inhibitors has become a cornerstone of acute coronary syndrome (ACS) …
P2Y12 inhibitors has become a cornerstone of acute coronary syndrome (ACS) …
Outcomes of prolonged dual anti-platelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a nationwide registry …
DM Christensen, AM Schjerning… - American Heart …, 2022 - Elsevier
Background Randomized controlled trials have shown a reduced risk of ischemic events
and an increased risk of bleeding in patients treated with prolonged dual anti-platelet …
and an increased risk of bleeding in patients treated with prolonged dual anti-platelet …